Compare PCRX & ACIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | ACIC |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 554.5M |
| IPO Year | 2010 | 2007 |
| Metric | PCRX | ACIC |
|---|---|---|
| Price | $23.35 | $10.46 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $30.25 | N/A |
| AVG Volume (30 Days) | ★ 361.9K | 269.5K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 6.33% |
| EPS Growth | ★ 107.44 | 39.61 |
| EPS | 0.07 | ★ 0.39 |
| Revenue | ★ $541,533,000.00 | $335,439,000.00 |
| Revenue This Year | $6.78 | N/A |
| Revenue Next Year | $8.54 | $1.00 |
| P/E Ratio | $334.57 | ★ $26.77 |
| Revenue Growth | ★ 26.04 | 13.07 |
| 52 Week Low | $18.80 | $9.80 |
| 52 Week High | $27.64 | $13.06 |
| Indicator | PCRX | ACIC |
|---|---|---|
| Relative Strength Index (RSI) | 52.48 | 45.88 |
| Support Level | $21.87 | $10.31 |
| Resistance Level | $23.95 | $11.39 |
| Average True Range (ATR) | 0.85 | 0.27 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 47.32 | 55.83 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.